AstraZeneca, Amgen’s asthma launch Tezspire picks up backing from England’s NICE


AstraZeneca and Amgen’s collaboration in developing the asthma medication Tezspire has achieved a significant milestone with the endorsement of England’s National Institute for Health and Care Excellence (NICE). NICE has recommended Tezspire for use within the National Health Service (NHS) in England, recognizing its potential to improve the management of asthma in patients. In this blog post, we will explore the key points surrounding England’s NICE backing of Tezspire, highlighting the implications for asthma treatment and patient care.

Key Points:

1. Tezspire: A New Approach to Asthma Management:

Tezspire is a new medication developed by AstraZeneca and Amgen in collaboration. It belongs to a class of drugs known as biologics and specifically targets a protein called thymic stromal lymphopoietin (TSLP) involved in the inflammatory processes associated with asthma. By blocking TSLP, Tezspire helps to reduce airway inflammation and improve asthma control in patients.

2. NICE Endorsement: Positive Impact on Asthma Treatment:

The recommendation of Tezspire by NICE is a significant endorsement for the medication’s effectiveness and safety in managing asthma. NICE assesses the clinical and cost-effectiveness of healthcare interventions, including medications, to provide recommendations to the NHS. NICE’s endorsement means that physicians in England can now prescribe Tezspire to suitable patients, increasing treatment options and potentially improving asthma outcomes for a larger population.

3. Addressing Unmet Needs in Asthma Management:

Asthma affects millions of people worldwide and is characterized by chronic inflammation of the airways, leading to symptoms such as wheezing, shortness of breath, and coughing. While existing treatments have been effective for many patients, there are still unmet needs in asthma management, especially in cases where standard therapies may not provide sufficient control. Tezspire offers a new therapeutic option for patients who experience inadequately controlled asthma symptoms despite other treatment approaches.

4. Personalized Medicine and Precision Therapy:

Tezspire’s approach to targeting TSLP demonstrates the potential of personalized medicine and precision therapy in asthma management. By specifically targeting the inflammatory mechanisms involved in asthma, Tezspire provides a tailored treatment option based on the underlying biology of the disease. This shift towards precision therapies represents a promising development in improving patient outcomes and reducing the burden of asthma on individuals and healthcare systems.

5. The Impact on Patient Care and Quality of Life:

NICE‘s endorsement of Tezspire is a positive development for patients with asthma in England. By expanding treatment options, it offers the potential for improved symptom control, reduced exacerbations, and enhanced overall quality of life. Asthma is a chronic condition that can significantly impact daily activities and overall well-being. The availability of targeted therapies like Tezspire brings renewed hope to patients, empowering them to better manage their symptoms and live life to the fullest.

6. Future Prospects: Expanding Access and Advancing Research:

With NICE‘s support, the use of Tezspire is expected to increase in England, benefiting a larger population of asthma patients. This increased usage will provide an opportunity to gather real-world data and further evaluate the medication’s effectiveness and safety in a broader patient population. Additionally, ongoing research and development in the field of asthma management will likely build upon the success of Tezspire, promising even more innovative treatment options and improved outcomes for patients in the future.


NICE’s endorsement of AstraZeneca and Amgen’s asthma medication Tezspire marks a significant advancement in asthma treatment and care. The recognition of Tezspire’s potential to improve asthma management offers hope for patients who have not achieved optimal control with current therapeutic options. As precision medicine continues to evolve, personalized treatment approaches like Tezspire show promise in addressing unmet needs in asthma care, enhancing patient outcomes, and improving quality of life. It is hoped that this endorsement will pave the way for expanded access to Tezspire in England and further research advancements in asthma management worldwide.